<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076570</url>
  </required_header>
  <id_info>
    <org_study_id>040099</org_study_id>
    <secondary_id>04-DK-0099</secondary_id>
    <nct_id>NCT00076570</nct_id>
  </id_info>
  <brief_title>Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation</brief_title>
  <official_title>Depletion Induction With Rabbit Anti-Thymocyte Globulin, Followed by Two Approaches Toward Monotherapy Immunosuppression in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will test the safety and effectiveness of a combination of three drugs followed by
      long-term treatment with just one drug in preventing organ rejection in kidney transplant
      patients. Current anti-rejection medicines are not completely effective in preventing
      rejection. This trial will test how well Thymoglobulin, Tacrolimus, and Sirolimus work
      together post-transplant and if the treatment can be reduced over time to control rejection
      with either Tacrolimus or Sirolimus alone.

      Candidates for kidney transplantation at the National Institutes of Health Clinical Center
      may participate in this 5-year study. Patients will be screened for eligibility with a
      medical history, physical examination, and blood tests.

      Participants will undergo the following tests and procedures:

        -  Central line placement: A large intravenous catheter (plastic tube, or IV line) is
           placed in a vein in the chest or neck under local anesthesia before the transplant
           surgery. The line remains in place for some time during the hospitalization to
           administer Thymoglobulin, antibiotics, and blood, if needed. The line is also used to
           collect blood samples.

        -  Leukapheresis: This procedure for collecting white blood cells is done before the
           transplant. The cells are studied to evaluate the patient's immune system. Whole blood
           is withdrawn through a catheter in an arm vein or through the central line and directed
           into a machine that separates the blood components by spinning. The white cells are
           removed and the red cells and plasma are returned to the body.

        -  Kidney transplant: Patients undergo kidney transplant surgery under general anesthesia.

        -  Immunosuppressive therapy: Patients receive thymoglobulin by vein for 4 days starting 1
           day before the transplant. They also take Tylenol, Benadryl and a steroid
           (methylprednisolone) to help reduce the side effects of the Thymoglobulin. After the
           transplant, patients receive Tacrolimus and Sirolimus by mouth once a day for 6 months
           and then either Tacrolimus or Sirolimus alone indefinitely. In addition, they take
           medicines to help prevent viral and fungal infections for 6 months because the
           immunosuppressive therapy leaves them vulnerable to infection.

        -  Follow-up visits: After hospital discharge, patients return to the Clinical Center twice
           a week for 4 weeks, then every 6 months for 1 year, and then yearly for another 4 years.
           At each visit, the patient's vital signs are checked and blood and urine samples are
           collected. Periodically, patients are also questioned about how they feel and how the
           transplant has affected their quality of life. Kidney biopsies (removal of a small
           amount of kidney tissue through a thin needle) are done when the patient begins
           single-drug immunosuppression (generally 6 months after transplantation) and 1 year
           after that. The biopsied tissue is examined to evaluate how well the kidney is
           responding to the treatment and to determine how to proceed with therapy.

        -  Routine laboratory tests: Routine tests, coordinated by the patient's local physician,
           are done 2 to 3 times a week for the first 2 to 3 months after transplantation, then
           weekly for several more months, and at least monthly for life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol facilitates the development of methods for determining whether transplant
      recipients have developed immune hyporesponsiveness or tolerance towards their allograft.
      These methods will involve the study of peripheral blood or biopsy tissue obtained at regular
      intervals from patients receiving kidney or combined kidney-pancreas allografts at the NIH
      Clinical Center. In addition, patients that have previously received a kidney or combined
      kidney-pancreas allograft will be evaluated using assays requiring peripheral blood
      mononuclear cells and/or biopsies. Assays developed under this protocol will be used in
      subsequent protocols to assess the effects of immune modulating treatment regimens and may
      eventually be used to direct clinical care or guide the withdrawal of immunosuppressive
      agents. However, patients enrolled in this protocol will not have any change in treatment
      based solely on the assays developed without being enrolled in an additional study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Rate of Allograft Rejection</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Rate of Significant Drug-associated Complications.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to sirolimus monotherapy and followed up for 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to tacrolimus monotherapy and followed up for 4 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Candidates for a kidney transplant at the Clinical Center.

        Willingness and legal ability to give informed consent.

        Availability of donor tissue for testing. This could include splenic or peripheral blood
        lymphocytes from a cadaveric donor or a willing living donor who consents to periodic
        phlebotomy for peripheral blood lymphocyte isolation.

        EXCLUSION CRITERIA:

        Immunosuppressive drug therapy at the time of or 2 months prior to enrollment.
        Specifically, candidates may not be taking prednisone, cyclosporine, tacrolimus,
        azathioprine, mycophenolate mofetil, anti-lymphocyte agents, cyclophosphamide,
        methotrexate, or other agents whose therapeutic effect is immunosuppressive.

        Any active malignancy or any history of any hematogenous malignancy or lymphoma. Patients
        with primary, cutaneous basal cell or squamous cell cancers may be enrolled providing the
        lesions are appropriately treated prior to transplant.

        Any known immunodeficiency syndrome, or other condition that, in the opinion of the
        investigators, would likely increase the risk of protocol participation or confound the
        interpretation of the data.

        Any history of sensitization to rabbits or extensive exposure to rabbits, as defined by
        symptomatic allergic response upon exposure to rabbits.

        Inability or unwillingness to comply with protocol monitoring and therapy including, among
        others, a history of noncompliance, circumstances where compliance with protocol
        requirements is not feasible due to living conditions, travel restrictions, access to
        urgent medical services, or access to anti-rejection drugs after the research protocol is
        completed.

        Peak Panel Reactive Antibody greater than 20%, or historically positive crossmatch due to
        HLA (human leukocyte antigen)-specific antibodies.

        HLA (human leukocyte antigen) identity between the donor and recipient.

        Pregnancy or unwillingness to practice an approved method of birth control. Acceptable
        methods of birth control may include barrier methods (condom and/or diaphragm with
        spermicide), oral contraceptives, Norplant, Depo-Provera or partner sterility.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monique E Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2004-DK-0099.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Eggers PW. Effect of transplantation on the Medicare end-stage renal disease program. N Engl J Med. 1988 Jan 28;318(4):223-9.</citation>
    <PMID>3275896</PMID>
  </reference>
  <reference>
    <citation>Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000 Mar 2;342(9):605-12.</citation>
    <PMID>10699159</PMID>
  </reference>
  <reference>
    <citation>Barry JM. Immunosuppressive drugs in renal transplantation. A review of the regimens. Drugs. 1992 Oct;44(4):554-66. Review.</citation>
    <PMID>1281071</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2004</study_first_submitted>
  <study_first_submitted_qc>January 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2004</study_first_posted>
  <results_first_submitted>August 7, 2013</results_first_submitted>
  <results_first_submitted_qc>August 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 16, 2013</results_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerance</keyword>
  <keyword>Kidney</keyword>
  <keyword>Transplant</keyword>
  <keyword>Polyclonal</keyword>
  <keyword>Antibody</keyword>
  <keyword>Kidney Transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Totally 31 patients were enrolled during August 2002 to October 2006 at NIH clinical center.</recruitment_details>
      <pre_assignment_details>The enrolled patients were pretreated with Thymoglobulin and methylprednisolone induction followed by combination therapy with both sirolimus (Rapa) and tacrolimus (FK) for 6 months. At 6 months, those without rejection on protocol biopsy with good tolerance to both drugs were randomized either Rapa or FK monotherapy and followed up for 48 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus Group</title>
          <description>Patients treated with sirolimus monotherapy from 6 months after combination therapy</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus Group</title>
          <description>Patients treated with tacrolimus monotherapy from 6 months after combination therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Drug intolerance</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis was performed using the patients who finished study.</population>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus Group</title>
          <description>Patients treated with sirolimus monotherapy from 6 months after combination therapy</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus Group</title>
          <description>Patients treated with tacrolimus monotherapy from 6 months after combination therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="13.1"/>
                    <measurement group_id="B2" value="45.0" spread="15.2"/>
                    <measurement group_id="B3" value="44.7" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Rate of Allograft Rejection</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Group</title>
            <description>Patients treated with sirolimus monotherapy from 6 months after combination therapy</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Group</title>
            <description>Patients treated with tacrolimus monotherapy from 6 months after combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Allograft Rejection</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Significant Drug-associated Complications.</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Group</title>
            <description>Patients treated with sirolimus monotherapy from 6 months after combination therapy</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Group</title>
            <description>Patients treated with tacrolimus monotherapy from 6 months after combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Significant Drug-associated Complications.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus Group</title>
          <description>Patients treated with sirolimus monotherapy from 6 months after combination therapy</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus Group</title>
          <description>Patients treated with tacrolimus monotherapy from 6 months after combination therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Monique Cho</name_or_title>
      <organization>NIDDK, National Institutes of Health</organization>
      <phone>3014355058</phone>
      <email>moniquec@intra.niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

